加载中
NASDAQHealthcareBiotechnology
最新数据
US$29.73
+US$0.22 · +0.75%
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
前收盘价
US$29.73
+US$0.22 · +0.75%
盘中时间采用ET。市场数据可能有所延迟。
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
日内区间
当前US$29.73
52周区间
当前US$29.73
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
86
深度低估
情绪
57
多空交织
风险
27
中等风险
动量
45
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
日内区间
当前US$29.73
52周区间
当前US$29.73
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 11.12亿 EUR | 2.76亿 EUR | 2.4亿 EUR | 2.41亿 EUR | 2.34亿 EUR |
| 销货成本 | 2973.6万 EUR | 3486.3万 EUR | — | — | 3.21亿 EUR |
| 毛利 | 10.83亿 EUR | 2.41亿 EUR | 2.4亿 EUR | 2.41亿 EUR | −8611.9万 EUR |
| 研究与开发 | 4.59亿 EUR | 3.35亿 EUR | 2.41亿 EUR | 2.7亿 EUR | 3.21亿 EUR |
| 销售、一般及管理费用 | 1.12亿 EUR | 9688万 EUR | 9425.2万 EUR | 1.03亿 EUR | 1.32亿 EUR |
| 营业费用 | 5.81亿 EUR | 4.29亿 EUR | 3.28亿 EUR | 3.72亿 EUR | 8544.9万 EUR |
| 利息收入 | 4633.9万 EUR | 8977.3万 EUR | 7960.8万 EUR | 1809.4万 EUR | — |
| 利息支出 | 221.7万 EUR | 91.1万 EUR | 177万 EUR | 915.5万 EUR | 872.7万 EUR |
| 折旧和摊销 | 5587.5万 EUR | 4549.9万 EUR | 4364.2万 EUR | 6556.6万 EUR | 831.3万 EUR |
| 营业利润 | 5.01亿 EUR | −1.88亿 EUR | −8826.3万 EUR | −1.31亿 EUR | −1.72亿 EUR |
| 净利润 | 3.21亿 EUR | 7408.2万 EUR | 2.12亿 EUR | −2.18亿 EUR | −1.03亿 EUR |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB994.06万0.09%108.2亿 USD0.44%US$206.49+3.00%
Schwab International Small-Cap Equity ETFSCHC296.93万0.05%55.33亿 USD0.06%US$49.47+0.84%
ALPS Medical Breakthroughs ETFSBIO251.53万1.31%1.91亿 USD0.50%US$55.04+2.03%
State Street SPDR Portfolio Developed World ex-US ETFSPDW144.17万0.00%404.62亿 USD0.03%US$49.98+0.64%
State Street SPDR S&P International Small Cap ETFGWX63.96万0.07%9.08亿 USD0.40%US$45.56+0.93%
State Street SPDR Portfolio Europe ETFSPEU5.3万0.01%6.83亿 USD0.07%US$53.13+0.68%
ProShares Ultra Nasdaq BiotechnologyBIB1.7万0.02%9320.36万 USD1.19%US$110.98+5.68%iShares Biotechnology ETFIBBSchwab International Small-Cap Equity ETFSCHCALPS Medical Breakthroughs ETFSBIOState Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR S&P International Small Cap ETFGWXState Street SPDR Portfolio Europe ETFSPEUProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
